Cardiac Function Biomarkers

Cross-source consensus on Cardiac Function Biomarkers from 1 sources and 7 claims.

1 sources · 7 claims

Benefits

Other

Highlighted claims

LVEF, NT-proBNP, GLS, and KCCQ were confirmatory secondary endpoints. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
Secondary endpoints were not significantly different between CDR132L and placebo. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
In the mITT population, LVEF increased by 7.2%, 7.7%, and 8.4% at month 6 in the placebo, 5 mg kg−1, and 10 mg kg−1 groups, respectively. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
LVEF increased from baseline to months 6 and 12 in all treatment groups. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
NT-proBNP decreased from baseline to months 6 and 12 in all treatment groups. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
GLS showed numerically greater improvement with CDR132L than placebo at month 6 but was not statistically significant. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
KCCQ overall summary scores improved across all groups from baseline to months 6 and 12. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial